DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $887,000 | -38.7% | 27,557 | -15.1% | 0.00% | -100.0% |
| Q4 2021 | $1,447,000 | -13.1% | 32,444 | -1.7% | 0.00% | 0.0% |
| Q3 2021 | $1,665,000 | -66.9% | 32,998 | -48.6% | 0.00% | -66.7% |
| Q2 2021 | $5,037,000 | +101.3% | 64,209 | +46.5% | 0.00% | +200.0% |
| Q1 2021 | $2,502,000 | -35.6% | 43,819 | -5.6% | 0.00% | -50.0% |
| Q4 2020 | $3,888,000 | +92.4% | 46,415 | -17.7% | 0.00% | +100.0% |
| Q3 2020 | $2,021,000 | +410.4% | 56,417 | +244.2% | 0.00% | – |
| Q2 2020 | $396,000 | +90.4% | 16,390 | +38.0% | 0.00% | – |
| Q1 2020 | $208,000 | 0.0% | 11,876 | -0.4% | 0.00% | – |
| Q4 2019 | $208,000 | +10.6% | 11,922 | -2.8% | 0.00% | – |
| Q3 2019 | $188,000 | – | 12,266 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |